SABR plus Lu-PSMA for limited prostate cancer spread
Part of Cancer, Kidney & urinary clinical trials.
This trial studies whether adding Lu-PSMA therapy to targeted, high-precision radiation (SABR) can better control prostate cancer that has spread to a small number of lymph nodes or bones. It may help by treating both visible spots with the most accurate radiation and PSMA-targeted drug therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re a man aged 18 or older and can sign consent
- Your prostate cancer has been confirmed by biopsy/pathology as prostate adenocarcinoma
- You previously had curative-intent treatment (radiation and/or surgery) for the original prostate cancer
- Your scan shows 1–5 cancer spots in lymph nodes or bones on a PSMA PET/CT scan
- You can safely receive SABR: your radiation oncologist says it’s appropriate
- Your blood counts and kidney function are adequate, and you have good daily-function status (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doing a second PET scan during treatment can help doctors decide if more precise radiation (SABR) should be used on all cancer spots in men with prostate cancer that has spread. It aims to see if this approach can better control the cancer while reducing side effects.
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial tests a precise type of radiation therapy (called SABR) for prostate cancer that has returned in the lymph nodes only. It aims to control the cancer with fewer side effects and might offer a treatment option when surgery or other standard treatments are no longer enough.
Hear when a new Oligometastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.